|  |  | 

India Top Headlines

Delta variant now reported in 85 countries globally, expected to become dominant lineage: WHO | India News


UNITED NATIONS: Delta variant, the significantly more transmissible strain of COVID-19, expected to become a “dominant lineage” if current trends continue, WHO warned after reported in 85 countries and continues to be detected in more places. worldwide.
The Covid-19 Weekly Epidemiological Update published on June 22 by the World Health Organization (WHO) said that globally, the Alpha variant has been reported in 170 countries, territories or areas, Beta in 119 countries, Gamma in 71 countries and Delta in 85 countries.
“Delta, now reported in 85 countries globally, continues to report in new countries in all WHO Regions, 11 of which were recently reported in the last two weeks,” the update said.
The WHO said that the four ‘Concerning Variants’ that are being closely monitored – Alpha, Beta, Gamma and Delta – are widespread and have been detected in all WHO regions. “The Delta variant is significantly more transmissible than the Alpha variant, and is expected to become a dominant lineage if current trends continue.”
The update said that India reported the highest number of new COVID19 cases, 441,976 during the past week (June 14-20, 2021), a decrease of 30 percent compared to the previous week. The highest number of new deaths was recorded in India (16,329 new deaths; 1.2 new deaths per 100,000; a decrease of 31%).
The South-East Asia Region reported more than 600,000 new cases and more than 19,000 new deaths, a decrease of 21% and 26%, respectively, compared to the previous week.
“The decreasing trends in the incidence of weekly cases and deaths in the Region are predominantly associated with the decreases reported in India,” the update said.
The WHO noted that since the last detailed update on June 8, new evidence on the phenotypic characteristics of the Delta variant has been published. “A study from Singapore showed that Delta variant infection was associated with higher odds of oxygen requirement, intensive care unit (ICU) admission, or death,” he said.
Furthermore, a study in Japan “estimating the relative instantaneous reproductive number (a measure of transmission at a specific point in time) showed that the Delta variant was associated with higher transmissibility” compared to the Alpha variant.
“Compared to variants circulating in Japan prior to December 2020, the relative instant replay number of Alpha was estimated to be 1.56 and Delta’s 1.78. Overall, this study showed that Delta was associated with 1.23 times higher transmissibility than Alpha, ”the update said.
The update also noted two studies that have provided evidence for the effectiveness of the Pfizer BioNTech-Comirnaty and AstraZeneca-Vaxzevria vaccines against the Delta variant. A study reports the efficacy of these vaccines against serious illness (hospitalization) due to Delta among people over 16 years of age in the UK.
Estimates of vaccine effectiveness against hospitalization due to Delta and Alpha variants for 14 days after the second dose were 96 percent and 95 percent respectively for Pfizer BioNTech-Comirnaty and 92 percent and 86 percent respectively, for AstraZeneca-Vaxzevria.
The effectiveness of a single dose against hospitalization for 21 days after immunization remained high for Pfizer BioNTech-Comirnaty at 94 percent against Delta and 83 percent against Alpha. The efficacy of a single dose of AstraZeneca-Vaxzevria against hospitalization was similar for the Delta and Alpha variants.
A second study from Scotland found that two doses of Pfizer BioNTech-Comirnaty were 83 percent and 79 percent effective against symptomatic disease and infection due to Delta, respectively, for 14 days after receiving the second dose in 15-year-olds. or more.
“Together, these studies suggest a moderately reduced VE to prevent disease and symptomatic infections due to the Delta variant compared to Alpha … The studies also provide further evidence of the importance of two doses of Pfizer BioNTech-Comirnaty and AstraZeneca-Vaxzevria in preventing hospitalization, symptomatic illness and infection due to Delta and Alpha variants, ”the update said.

Original source